vs

Side-by-side financial comparison of Empire State Realty OP, L.P. (ESBA) and NATURES SUNSHINE PRODUCTS INC (NATR). Click either name above to swap in a different company.

Empire State Realty OP, L.P. is the larger business by last-quarter revenue ($199.2M vs $123.8M, roughly 1.6× NATURES SUNSHINE PRODUCTS INC). Empire State Realty OP, L.P. runs the higher net margin — 16.1% vs 3.3%, a 12.8% gap on every dollar of revenue. On growth, NATURES SUNSHINE PRODUCTS INC posted the faster year-over-year revenue change (4.7% vs 0.8%). Empire State Realty OP, L.P. produced more free cash flow last quarter ($50.6M vs $7.6M). Over the past eight quarters, NATURES SUNSHINE PRODUCTS INC's revenue compounded faster (5.6% CAGR vs 4.9%).

Empire State Realty OP, L.P. is a real estate operating partnership focused on owning, managing, and leasing premium commercial and retail properties primarily in the New York City metropolitan area. Its portfolio includes iconic landmarks like the Empire State Building, serving corporate tenants, retail brands and tourism-related business segments.

Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.

ESBA vs NATR — Head-to-Head

Bigger by revenue
ESBA
ESBA
1.6× larger
ESBA
$199.2M
$123.8M
NATR
Growing faster (revenue YoY)
NATR
NATR
+3.9% gap
NATR
4.7%
0.8%
ESBA
Higher net margin
ESBA
ESBA
12.8% more per $
ESBA
16.1%
3.3%
NATR
More free cash flow
ESBA
ESBA
$43.0M more FCF
ESBA
$50.6M
$7.6M
NATR
Faster 2-yr revenue CAGR
NATR
NATR
Annualised
NATR
5.6%
4.9%
ESBA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ESBA
ESBA
NATR
NATR
Revenue
$199.2M
$123.8M
Net Profit
$32.2M
$4.1M
Gross Margin
72.5%
Operating Margin
17.8%
4.3%
Net Margin
16.1%
3.3%
Revenue YoY
0.8%
4.7%
Net Profit YoY
71.2%
1379.4%
EPS (diluted)
$0.11
$0.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESBA
ESBA
NATR
NATR
Q4 25
$199.2M
$123.8M
Q3 25
$197.7M
$128.3M
Q2 25
$191.3M
$114.8M
Q1 25
$180.1M
$113.2M
Q4 24
$197.6M
$118.2M
Q3 24
$199.6M
$114.6M
Q2 24
$189.5M
$110.6M
Q1 24
$181.2M
$111.0M
Net Profit
ESBA
ESBA
NATR
NATR
Q4 25
$32.2M
$4.1M
Q3 25
$13.6M
$5.3M
Q2 25
$11.4M
$5.3M
Q1 25
$15.8M
$4.7M
Q4 24
$18.8M
$-321.0K
Q3 24
$22.8M
$4.3M
Q2 24
$28.6M
$1.3M
Q1 24
$10.2M
$2.3M
Gross Margin
ESBA
ESBA
NATR
NATR
Q4 25
72.5%
Q3 25
73.3%
Q2 25
71.7%
Q1 25
72.1%
Q4 24
72.0%
Q3 24
71.3%
Q2 24
71.4%
Q1 24
71.2%
Operating Margin
ESBA
ESBA
NATR
NATR
Q4 25
17.8%
4.3%
Q3 25
19.9%
7.0%
Q2 25
18.4%
3.7%
Q1 25
14.3%
5.4%
Q4 24
21.7%
3.8%
Q3 24
22.7%
4.6%
Q2 24
20.8%
5.1%
Q1 24
17.1%
4.2%
Net Margin
ESBA
ESBA
NATR
NATR
Q4 25
16.1%
3.3%
Q3 25
6.9%
4.2%
Q2 25
6.0%
4.6%
Q1 25
8.8%
4.2%
Q4 24
9.5%
-0.3%
Q3 24
11.4%
3.8%
Q2 24
15.1%
1.2%
Q1 24
5.6%
2.1%
EPS (diluted)
ESBA
ESBA
NATR
NATR
Q4 25
$0.11
$0.23
Q3 25
$0.05
$0.30
Q2 25
$0.04
$0.28
Q1 25
$0.05
$0.25
Q4 24
$0.07
$-0.02
Q3 24
$0.08
$0.23
Q2 24
$0.10
$0.07
Q1 24
$0.03
$0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESBA
ESBA
NATR
NATR
Cash + ST InvestmentsLiquidity on hand
$132.7M
$93.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$161.6M
Total Assets
$4.5B
$261.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESBA
ESBA
NATR
NATR
Q4 25
$132.7M
$93.9M
Q3 25
$154.1M
$95.6M
Q2 25
$94.6M
$81.3M
Q1 25
$187.8M
$86.5M
Q4 24
$385.5M
$84.7M
Q3 24
$421.9M
$78.7M
Q2 24
$535.5M
$68.7M
Q1 24
$333.6M
$77.8M
Total Debt
ESBA
ESBA
NATR
NATR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
$2.1M
Stockholders' Equity
ESBA
ESBA
NATR
NATR
Q4 25
$161.6M
Q3 25
$166.7M
Q2 25
$163.7M
Q1 25
$167.1M
Q4 24
$161.0M
Q3 24
$162.6M
Q2 24
$156.4M
Q1 24
$159.7M
Total Assets
ESBA
ESBA
NATR
NATR
Q4 25
$4.5B
$261.1M
Q3 25
$4.1B
$264.8M
Q2 25
$4.1B
$254.9M
Q1 25
$4.1B
$252.7M
Q4 24
$4.5B
$240.9M
Q3 24
$4.4B
$245.3M
Q2 24
$4.4B
$235.8M
Q1 24
$4.2B
$247.3M
Debt / Equity
ESBA
ESBA
NATR
NATR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.01×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESBA
ESBA
NATR
NATR
Operating Cash FlowLast quarter
$249.1M
$9.9M
Free Cash FlowOCF − Capex
$50.6M
$7.6M
FCF MarginFCF / Revenue
25.4%
6.1%
Capex IntensityCapex / Revenue
99.6%
1.9%
Cash ConversionOCF / Net Profit
7.74×
2.41×
TTM Free Cash FlowTrailing 4 quarters
$109.3M
$28.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESBA
ESBA
NATR
NATR
Q4 25
$249.1M
$9.9M
Q3 25
$105.3M
$18.5M
Q2 25
$26.7M
$4.3M
Q1 25
$83.1M
$2.6M
Q4 24
$260.9M
$12.2M
Q3 24
$102.8M
$9.6M
Q2 24
$37.1M
$1.3M
Q1 24
$70.9M
$2.2M
Free Cash Flow
ESBA
ESBA
NATR
NATR
Q4 25
$50.6M
$7.6M
Q3 25
$72.8M
$16.8M
Q2 25
$-55.1M
$3.0M
Q1 25
$41.1M
$1.5M
Q4 24
$88.0M
$10.0M
Q3 24
$-65.1M
$7.9M
Q2 24
$19.5M
$-2.0M
Q1 24
$23.2M
$-1.5M
FCF Margin
ESBA
ESBA
NATR
NATR
Q4 25
25.4%
6.1%
Q3 25
36.8%
13.1%
Q2 25
-28.8%
2.6%
Q1 25
22.8%
1.3%
Q4 24
44.5%
8.5%
Q3 24
-32.6%
6.9%
Q2 24
10.3%
-1.9%
Q1 24
12.8%
-1.4%
Capex Intensity
ESBA
ESBA
NATR
NATR
Q4 25
99.6%
1.9%
Q3 25
16.5%
1.3%
Q2 25
42.8%
1.2%
Q1 25
23.4%
1.0%
Q4 24
87.5%
1.9%
Q3 24
84.1%
1.5%
Q2 24
9.3%
3.0%
Q1 24
26.3%
3.3%
Cash Conversion
ESBA
ESBA
NATR
NATR
Q4 25
7.74×
2.41×
Q3 25
7.72×
3.46×
Q2 25
2.35×
0.81×
Q1 25
5.27×
0.55×
Q4 24
13.88×
Q3 24
4.51×
2.21×
Q2 24
1.30×
0.97×
Q1 24
6.94×
0.94×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESBA
ESBA

Real Estate Segment$163.8M82%
Observatory Segment$35.2M18%

NATR
NATR

Other$68.1M55%
General Health Products$20.2M16%
Digestive Products$13.8M11%
Cardiovascular Products$12.1M10%
Personal Care Products$4.4M4%
Immunity Products$3.1M3%
Weight Management Products$2.1M2%

Related Comparisons